Vascular Dementia vs. Alzheimer’s Disease

Neurodegenerative and cerebrovascular cognitive disorders represent an escalating global public health challenge, driven by an aging worldwide population and an increasingly complex burden of cardiovascular comorbidities. Among the various etiologies underlying adult-onset cognitive decline, Alzheimer’s disease and vascular dementia together account for up to 85 percent of all clinical diagnoses. While historically viewed as discrete clinical and pathological entities—one characterized by intrinsic protein-misfolding cascades and the other by macro- or microvascular ischemic insults—contemporary neuroscience recognizes a profound and intricate interplay between the cerebral vasculature and neurodegenerative processes. Despite this mechanistic overlap, distinguishing between primary vascular dementia and primary Alzheimer’s disease remains a fundamental cornerstone of clinical neurology, geriatric medicine, and neuropsychiatry.

The clinical imperative for establishing an early and precise differential diagnosis has never been more urgent. With the clinical advent of targeted disease-modifying therapies, such as monoclonal antibodies directed against amyloid-beta proteopathies, misattribution of vascular cognitive impairment to Alzheimer’s pathology—or vice versa—carries profound therapeutic, financial, and safety ramifications. Furthermore, the management paradigms for these two disorders diverge substantially: whereas Alzheimer’s therapeutics primarily focus on neurochemical augmentation and biological plaque clearance, vascular dementia management hinges on rigorous secondary stroke prevention, hemodynamic optimization, and the mitigation of systemic end-organ vascular injury. Erroneous diagnosis can lead to inappropriate treatment regimens, failure to implement vital secondary prevention measures, and inadequate prognostic counseling for patients and their families.

This comprehensive clinical treatise provides an exhaustive, evidence-based exploration of the structural, molecular, biomarker, neuropsychological, and therapeutic distinctions between vascular dementia and Alzheimer’s disease. Drawing upon landmark clinicopathological discoveries, contemporary consensus diagnostic frameworks, and cutting-edge fluid and molecular imaging advancements, this document outlines the pathophysiology, clinical trajectories, differential diagnostic algorithms, and holistic management pathways required to navigate the diagnostic divide between cerebrovascular injury and primary neurodegeneration.

1. Introduction: Distinguishing Vascular Dementia from Alzheimer’s Disease

1.1 Clinical Definitions and Global Epidemiology

Dementia, classified under the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) as Major Neurocognitive Disorder, is defined by substantial cognitive decline from a previous level of performance in one or more cognitive domains—including complex attention, executive function, learning and memory, language, perceptual-motor, or social cognition—sufficient to compromise independence in everyday activities. Worldwide, an estimated 55 million individuals live with dementia, a figure projected to surpass 139 million by 2050 according to the World Health Organization. Within this immense epidemiological footprint, Alzheimer’s disease represents the predominant etiology, comprising approximately 60 to 70 percent of all validated clinical cases.

Vascular dementia constitutes the second most prevalent form of neurocognitive disorder, accounting for approximately 15 to 20 percent of cases in North America and Europe, and exceeding 30 percent in certain East Asian cohorts where subcortical microvascular disease and arteriolosclerosis are particularly widespread. Rather than representing a monolithic pathology, vascular dementia encompasses a heterogeneous spectrum of cognitive deficits arising from cerebral infarction, intracerebral hemorrhage, microvascular small vessel disease, or chronic systemic hypoperfusion. The global burden of both disorders is strongly age-dependent; however, the age-adjusted incidence of vascular dementia exhibits unique dynamics directly correlated with population-level cardiovascular risk control, stroke survival rates, and regional disparities in the management of metabolic disease.

Accurate differentiation between these two conditions is essential not merely for epidemiological classification, but for direct clinical decision-making. Prognostic trajectories, functional preservation strategies, and preventative regimens depend heavily on establishing whether cognitive deterioration is driven by an unremitting, progressive neurodegenerative proteinopathy or by cumulative, potentially modifiable ischemic parenchymal destruction. As the global healthcare landscape confronts the socioeconomic and human toll of cognitive decline, the capacity to delineate vascular mechanisms from primary amyloid- and tau-mediated injury serves as the bedrock of modern neurogeriatric care.

1.2 The Diagnostic Challenge: Symptomatic Overlap and Diagnostic Confusion

In clinical practice, disentangling vascular dementia from Alzheimer’s disease frequently presents significant diagnostic ambiguity, particularly during the moderate to advanced stages of disease progression. Both pathological processes ultimately converge on common final pathways of neurodegeneration, synaptic disconnection, neurotransmitter failure, and neuronal apoptosis. Consequently, advanced presentations of both conditions manifest with debilitating episodic memory deficits, communicative impairments, loss of visuospatial orientation, severe executive dysregulation, and profound behavioral disturbances, effectively masking the unique features that characterized their initial clinical presentations.

The diagnostic challenge is further compounded by the extensive sharing of systemic vascular risk factors. Atherosclerosis, chronic essential hypertension, type 2 diabetes mellitus, hyperlipidemia, and elevated homocysteine levels do not solely cause cerebrovascular injury; they simultaneously compromise blood-brain barrier integrity, accelerate cerebral amyloid angiopathy, reduce parenchymal clearance of toxic peptides, and foster neuroinflammatory environments that accelerate Alzheimer’s pathology. When an elderly patient presents with gradual cognitive decline alongside neuroimaging evidence of both cerebral atrophy and diffuse periventricular white matter changes, the clinician faces a complex task: determining which pathological process represents the primary driver of functional decline, or whether the patient is experiencing the additive effects of mixed dementia.

Diagnostic confusion carries substantial clinical risks. Misattributing vascular cognitive impairment to Alzheimer’s disease frequently leads to missed windows of opportunity for aggressive secondary vascular prevention, exposing patients to preventable secondary strokes, microinfarcts, and accelerating subcortical ischemia. Conversely, misidentifying atypical presentations of Alzheimer’s disease as purely vascular can prevent timely initiation of approved symptomatic therapies, exclusion from clinical trials, or inappropriate administration of antiplatelet or anticoagulant regimens that may elevate cerebral microhemorrhage risks in individuals with extensive cerebral amyloid angiopathy. Fortunately, the continuous refinement of multimodal magnetic resonance imaging (MRI) and the rapid clinical translation of biofluid markers are revolutionizing this diagnostic paradigm, transitioning the field away from purely observational phenomenology toward biological precision.

1.3 Scope, Purpose, and Framework of This Clinical Comparison

The objective of this clinical monograph is to establish a rigorous, highly articulated comparative framework that delineates the fundamental biological, neuroanatomical, neuroimaging, neuropsychological, and therapeutic boundaries separating vascular dementia from Alzheimer’s disease. By examining each disorder from its molecular originators to its macroscopic clinical manifestations, this treatise equips clinicians, researchers, and advanced healthcare practitioners with the diagnostic tools required to dissect complex cognitive presentations.

This analysis is organized along a sequential, multi-tiered framework. First, it investigates the distinct pathophysiological architectures of each condition, contrasting ischemic injury cascades and microvascular disruptions against amyloid-beta cascades and hyperphosphorylated tau neurofibrillary tangles. Second, it explores the phenotypic differences between the two disorders, contrasting the abrupt, stepwise, fronto-subcortical presentation typical of vascular dementia with the insidious, continuous, amnestic presentation characteristic of classical Alzheimer’s disease. Third, it provides a rigorous, parameter-by-parameter comparative analysis via dedicated tabular and textual synthesis, addressing imaging signatures, biofluid assays, and neurochemical interventions.

Finally, this framework directly addresses the clinical realities of mixed dementia and comorbidity, recognizing that the dichotomization of neurodegeneration and vascular disease, while conceptually necessary, often dissolves in real-world geriatric populations. By detailing validated clinical diagnostic algorithms, risk stratification protocols, and holistic multidisciplinary management pathways, this document aims to elevate the standard of clinical differentiation from empiric guesswork to biomarker-verified, personalized neurology.

2. Comprehensive Overview of Vascular Dementia

2.1 Pathophysiology and Cerebrovascular Mechanisms

Vascular dementia is characterized by cognitive impairment attributable to cerebrovascular disease that compromises cerebral blood flow, depletes metabolic reserves, and causes focal, multifocal, or diffuse parenchymal necrosis. At the cellular level, the pathological cascade is triggered by cerebral ischemia or hemorrhage, which destabilizes the neurovascular unit (NVU)—a functional multicellular complex comprising brain capillary endothelial cells, mural pericytes, perivascular astrocytic end-feet, microglia, and local interneurons. When local cerebral perfusion falls below the critical threshold required for cellular homeostasis (typically below 18 to 20 mL/100g/min), the disruption of sodium-potassium adenosine triphosphatase (Na+/K+-ATPase) pumps initiates massive neuronal depolarization, uncontrolled extracellular glutamate accumulation, excitotoxic intracellular calcium influx, mitochondrial permeability transition pore opening, and the generation of reactive oxygen and nitrogen species.

Central to the most common forms of vascular dementia is cerebral small vessel disease (cSVD), which pathologically manifests as arteriolosclerosis, lipohyalinosis, and fibrinoid necrosis of the deep, penetrating, terminal end-arteries supplying the basal ganglia, internal capsule, thalamus, and deep periventricular white matter. These end-arteries lack collateral anastomoses, rendering their dependent territories exceptionally vulnerable to chronic hypoperfusion and acute occlusion. Arteriolosclerosis leads to severe thickening of the vessel media, smooth muscle cell loss, collagenous replacement, and progressive luminal stenosis. In parallel, cerebral amyloid angiopathy (CAA)—characterized by the selective deposition of amyloid-beta within the adventitia and media of cortical and leptomeningeal arterioles—induces vascular fragility, recurrent cortical microbleeds, and superficial siderosis, serving as a non-atherosclerotic vascular mechanism that directly drives cognitive impairment.

The structural consequence of these microvascular abnormalities is the profound disruption of subcortical white matter connectivity. The myelinated axonal tracts traversing the centrum semiovale, corpus callosum, and external/internal capsules form the structural infrastructure of reciprocal fronto-subcortical loops, connecting the prefrontal cortex with the basal ganglia and thalamus. Ischemia induces oligodendrocyte apoptosis, localized demyelination, clasmatodendrosis (astrocytic fragmentation), and secondary axonal degeneration. As these pathways disconnect, the brain experiences an irreversible disruption of information processing speed, complex executive control, and working memory synthesis. Concurrently, chronic endothelial dysfunction degrades the structural integrity of the blood-brain barrier (BBB), permitting the perivascular extravasation of plasma proteins such as fibrinogen and albumin into the parenchymal neuropil. This leakage activates microglia, triggers the release of pro-inflammatory cytokines (including interleukin-1 beta, tumor necrosis factor-alpha, and matrix metalloproteinases), and establishes a chronic neuroinflammatory microenvironment that sustains secondary neurodegeneration well beyond the initial ischemic event.

2.2 Etiological Subtypes: Multi-Infarct, Subcortical Ischemic, and Post-Stroke

Vascular dementia is an umbrella diagnosis comprising several distinct pathophysiological and anatomical subtypes, each dictated by the caliber, distribution, and mechanism of the underlying vascular pathology:

• Multi-Infarct Dementia (Cortical Vascular Dementia): This classical variant arises from recurrent thromboembolic, atherothrombotic, or cardiogenic occlusions of medium-to-large-caliber cerebral arteries (such as the middle cerebral artery, anterior cerebral artery, or posterior cerebral artery and their primary branches). These events result in multiple, geographically discrete, macroscopic cortical and subcortical territorial infarcts. The cognitive impairment stems from the cumulative loss of cerebral functional parenchyma and the interruption of distributed cortical networks, frequently manifesting with focal lateralized deficits (aphasia, apraxia, hemiparesis, or visual field deficits) superimposed on cognitive decline.
• Subcortical Ischemic Vascular Dementia (SIVD / Binswanger’s Disease): Representing the most frequent form of vascular cognitive impairment, SIVD is driven by severe microvascular small vessel disease. It features two interrelated neuropathological lesions: multiple cavitated lacunar infarcts (typically measuring less than 15 millimeters in diameter) in the basal ganglia, thalamus, and internal capsule; and diffuse, confluent, ischemic white matter injury (leukoaraiosis) throughout the periventricular and deep centrum semiovale. This phenotype induces a pure subcortical syndrome characterized by profound psychomotor slowing, executive dysfunction, emotional lability, and early gait apraxia, often in the absence of overt, documented clinical strokes.
• Strategic Infarct Dementia: This subtype is caused by solitary, highly localized ischemic or hemorrhagic strokes occurring within critical, highly interconnected functional neuroanatomical nodes. A strategic infarct in the paramedian or tuberothalamic territories of the thalamus, the anterior cingulate cortex, the angular gyrus, the genu of the internal capsule, or the caudate nucleus can instantly induce severe, permanent neurocognitive collapse. Because these focal structures serve as essential gateways for cognitive integration, memory retrieval, and sustained attention, a focal lesion measuring only a few millimeters can clinically mimic a widespread neurodegenerative process.
• Post-Stroke Dementia (PSD): Defined clinically as any dementia that emerges acutely or subacutely within three to six months following an overt, clinically validated stroke event. Post-stroke dementia encompasses cases where an acute ischemic or hemorrhagic stroke directly depletes remaining cognitive reserve, or where stroke-induced neuroinflammation unmasks previously subclinical, latent neurodegenerative processes. Approximately 10 to 30 percent of stroke survivors fulfill criteria for dementia at three months post-event, with long-term incidence increasing exponentially in the presence of pre-existing cerebral small vessel disease.

2.3 Clinical Presentation, Stepwise Progression, and Executive Dysfunction

The clinical presentation of vascular dementia differs fundamentally from the classic insidious memory loss seen in degenerative dementias. The hallmark trajectory of classical multi-infarct dementia is characterized by an abrupt, sudden clinical onset followed by a fluctuating, stepwise deterioration. In this pattern, cognitive or functional drops correspond temporally with acute ischemic or microvascular events, interspersed with periods of stability or even modest partial functional recovery as compensatory neuroplasticity engages. In subcortical ischemic vascular dementia, however, the trajectory may be more insidious and continuous, driven by the steady, progressive accrual of diffuse white matter microangiopathy and incomplete ischemia, which can complicate clinical differentiation from degenerative disorders.

Neuropsychologically, vascular cognitive impairment is characterized by prominent early deficits in executive function, cognitive flexibility, complex concept formation, and information processing speed, with relative preservation of episodic memory storage. Patients struggle profoundly with tasks requiring initiation, sequencing, response inhibition, planning, and abstract reasoning (governed by the dorsolateral and orbitofrontal prefrontal-subcortical circuits). While these individuals frequently perform poorly on unprompted free-recall memory assessments, their underlying deficit is primarily driven by retrieval failure rather than true storage or encoding failure. When provided with semantic cues or categorical recognition choices, their retrieval performance often normalizes substantially—a dissociation reflecting the structural integrity of the hippocampus and entorhinal cortex in the face of interrupted frontostriatal retrieval pathways.

In addition to cognitive deficits, vascular dementia frequently presents with early, prominent motor and autonomic signs. Patients typically develop an early gait disorder, often termed subcortical gait apraxia, “marche à petits pas,” or lower-body parkinsonism, characterized by a wide base, magnetic foot clearance, short shuffling strides, and preserved arm swing without the resting tremor seen in Parkinson’s disease. Pseudobulbar signs are frequent, including emotional incontinence (involuntary, inappropriate outbursts of laughing or crying, termed pseudobulbar affect), dysarthria, and dysphagia. Furthermore, early urinary urgency, frequency, and urge incontinence occur regularly due to the uninhibited detrusor reflex resulting from the disruption of cortical inhibitory tracts descending to the sacral spinal cord. Neuropsychiatric symptoms, particularly apathy, abulia, depression, and psychomotor agitation, are common and directly correlate with the severity of fronto-subcortical white matter disruption.

2.4 Diagnostic Criteria and Neuroimaging Markers

The formal clinical diagnosis of vascular dementia requires objective evidence of cognitive decline, verified cerebrovascular disease, and a demonstrable temporal or anatomical relationship linking the two. Several diagnostic frameworks have been established, among which the National Institute of Neurological Disorders and Stroke and Association Internationale pour la Recherche et l’Enseignement en Neurosciences (NINDS-AIREN) criteria remain a widely utilized reference standard, alongside the updated criteria established by the Vascular Impairment of Cognition Classification Consensus Study (VICCCS) and the Vascular Cognitive Disorders (VASCOG) guidelines endorsed by the International Society for Vascular Behavioral and Cognitive Disorders.

Under these criteria, establishing cerebrovascular etiology depends upon structural neuroimaging, with high-field (3.0-Tesla preferred) Magnetic Resonance Imaging (MRI) serving as the diagnostic standard. Neuroimaging features are categorized and reported according to the Standards for Reporting Vascular Changes on Neuroimaging (STRIVE) consensus criteria:

• Recent Small Subcortical Infarcts: Evidenced on diffusion-weighted imaging (DWI) as hyperintense signals reflecting acute, cellular cytotoxic edema in the territory of a single penetrating end-artery, later transitioning to small fluid-filled cavities on T1 and FLAIR sequences.
• Lacunes of Presumed Vascular Origin: Round or ovoid subcortical, fluid-filled cavities between 3 and 15 mm in diameter, exhibiting cerebrospinal fluid (CSF)-like hypointensity on T1-weighted images and FLAIR (often surrounded by a hyperintense rim) and hyperintensity on T2-weighted imaging, localized primarily to the basal ganglia, internal capsule, and deep white matter.
• White Matter Hyperintensities (WMH) of Presumed Vascular Origin: Evident as confluent or patchy hyperintense signals on T2-weighted and Fluid-Attenuated Inversion Recovery (FLAIR) sequences, and isointense/hypointense on T1-weighted sequences (leukoaraiosis). These are clinically staged using the Fazekas scale, where Fazekas Grade 2 (beginning confluence) and Grade 3 (large, confluent, irregular white matter hyperintensities extending into the deep and subcortical white matter) are strongly correlated with vascular cognitive decline.
• Perivascular Spaces (Virchow-Robin Spaces): Fluid-filled spaces surrounding small arteries and arterioles, appearing as round or linear punctate structures <3 mm with CSF-like signal intensity, particularly prominent in the basal ganglia and centrum semiovale, serving as an imaging proxy for cerebral glymphatic and microvascular clearance dysfunction.
• Cerebral Microbleeds (CMB): Small (2 to 10 mm), round or ovoid signal voids with associated blooming artifacts visualized on blood-sensitive MRI sequences such as Gradient Recalled Echo (T2*-GRE) and Susceptibility-Weighted Imaging (SWI). Deep, basal ganglia-centered microbleeds indicate chronic hypertensive arteriolosclerosis, whereas strictly lobar, cortico-subcortical microbleeds strongly suggest the presence of cerebral amyloid angiopathy.
• Brain Atrophy: Both generalized parenchymal volume loss and focal cortical thinning secondary to subcortical deafferentation, which must be distinguished from the selective, out-of-proportion medial temporal lobe atrophy typical of neurodegenerative tauopathies.

3. Comprehensive Overview of Alzheimer’s Disease

3.1 Neuropathology: Amyloid-Beta Plaques and Neurofibrillary Tangles

Alzheimer’s disease is an insidious, progressive, neurodegenerative proteopathy characterized neuropathologically by two defining hallmarks: extracellular senile plaques composed of aggregated amyloid-beta (Aβ) peptides and intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein. The pathogenesis of the condition is historically rooted in the original clinicopathological observations of Alois Alzheimer, who in 1906 identified these profound structural aberrations in the post-mortem brain tissue of his patient, Auguste Deter. Decades of biochemical and genetic research have elucidated the molecular pathways driving these pathological protein assemblies.

The initiation of Alzheimer’s disease pathology is widely conceptualized through the amyloid cascade hypothesis. Amyloid-beta is generated through the aberrant sequential cleavage of the amyloid precursor protein (APP)—a transmembrane glycoprotein located on chromosome 21. In the pathological amyloidogenic pathway, APP undergoes initial cleavage by the transmembrane aspartyl protease beta-site APP cleaving enzyme 1 (BACE1), liberating a soluble beta-APP fragment and leaving behind a membrane-bound 99-amino-acid C-terminal fragment (C99). Subsequently, the intramembranous gamma-secretase complex—a tetrameric enzymatic assembly comprising presenilin 1 (PSEN1), presenilin 2 (PSEN2), nicastrin, anterior pharynx-defective 1 (APH-1), and presenilin enhancer 2 (PEN-2)—cleaves C99 at variable positions. This cleavage yields Aβ peptides of varying amino acid lengths, predominantly Aβ40 and the highly hydrophobic, aggregation-prone Aβ42 peptide. While monomeric Aβ is physiologically cleared, an imbalance between production and clearance leads to the self-assembly of Aβ42 into soluble oligomers, protofibrils, and ultimately insoluble beta-sheet fibrils that precipitate as parenchymal senile plaques.

While amyloid accumulation represents an essential and early trigger, tau pathology and neurofibrillary degeneration correlate much more closely with clinical cognitive decline, synaptic loss, and neurodegeneration. Microtubule-associated protein tau, encoded by the MAPT gene on chromosome 17, normally functions to bind and stabilize the tubulin cytoskeleton within axonal compartments. In Alzheimer’s disease, pathological kinases—including glycogen synthase kinase-3 beta (GSK-3β), cyclin-dependent kinase 5 (CDK5), and microtubule affinity-regulating kinase (MARK)—overwhelm cellular phosphatases, inducing pathological hyperphosphorylation of tau at specific residues (e.g., threonine 181, threonine 217, threonine 231, and serine 396). Hyperphosphorylated tau detaches from microtubules, causing cytoskeletal collapse and axonal transport failure. The detached tau misfolds into paired helical filaments (PHFs), coalescing within neuronal somata as neurofibrillary tangles and within dystrophic neurites surrounding amyloid plaques.

The spatiotemporal dissemination of tau pathology follows a stereotypic anatomical hierarchy historically described by Heiko and Eva Braak through Braak Staging:

• Braak Stages I–II (Transentorhinal Stages): Pathological tau aggregates are strictly confined to the transentorhinal and entorhinal cortices, remaining clinically silent or manifesting as subtle subjective cognitive decline.
• Braak Stages III–IV (Limbic Stages): Tau pathology spreads trans-synaptically to involve the hippocampus proper (CA1, subiculum), amygdala, and basolateral limbic structures, correlating clinically with the emergence of amnestic mild cognitive impairment.
• Braak Stages V–VI (Isocortical / Neocortical Stages): Neurofibrillary tangles invade widespread association cortices, primary sensory-motor regions, and multimodal neocortex, directly precipitating severe global dementia, aphasia, apraxia, and total functional dependency.

This molecular proteopathy culminates in profound synaptic loss—the single strongest morphological correlate of cognitive failure—and the selective loss of cholinergic projection neurons residing within the basal forebrain (nucleus basalis of Meynert), producing a profound neocortical deficiency in acetylcholine that underpins early attentional and memory encoding failures.

3.2 Disease Stages: Preclinical, Mild Cognitive Impairment, and Dementia

Modern clinical neurology conceptualizes Alzheimer’s disease not as an acute syndrome, but as a continuous, biological disease spectrum spanning several decades, stratified into three distinct stages:

1. Preclinical Alzheimer’s Disease: This stage is characterized by the presence of in vivo biological evidence of Alzheimer’s neuropathology (amyloid-beta deposition, accompanied in later preclinical phases by early tau deposition and subtle cortical neurodegeneration) in an individual who remains completely cognitively intact. Validated psychometric evaluations and functional capacity remain entirely within normal limits. Longitudinal positron emission tomography (PET) and cerebrospinal fluid (CSF) studies establish that this preclinical incubation phase can persist for 15 to 25 years before the clinical manifestation of symptoms, providing a crucial biological window for preventative intervention.
2. Amnestic Mild Cognitive Impairment (aMCI) Due to Alzheimer’s Disease: This stage represents the symptomatic transitional phase. Patients or reliable collateral informants report an insidious decline in cognitive capacity, most characteristically in the domain of episodic memory. Objective neuropsychological testing demonstrates performance falling 1.5 standard deviations or more below age- and education-matched normative means on standardized delayed recall measures. Crucially, the patient’s basic and complex instrumental activities of daily living (such as managing finances, handling complex medications, and operating household appliances) remain largely preserved, although these tasks may require increased effort, compensatory strategies, or more time. Individuals with aMCI harbor an annual conversion rate to overt dementia of approximately 10 to 15 percent per year.
3. Alzheimer’s Disease Dementia: This stage begins when cognitive deficits become sufficiently severe to compromise functional autonomy, requiring persistent external assistance with instrumental and, eventually, basic activities of daily living. Dementia is further stratified into:
   • Mild Dementia: Notable interference with complex daily tasks (e.g., getting lost in unfamiliar environments, difficulty with household administration), clear social withdrawal, mild expressive anomia, and prominent short-term forgetfulness.
   • Moderate Dementia: Complete inability to live independently. Severe retrograde and anterograde amnesia, clear temporal and spatial disorientation, emerging apraxia (inability to execute motor acts like dressing or using utensils despite intact motor strength), sensory agnosia, and prominent behavioral symptoms (wandering, agitation, sundowning, and paranoid delusions).
   • Severe Dementia: Profound, catastrophic cognitive and physical dissolution. Loss of intelligible speech (progressing to echolalia or complete mutism), inability to ambulate, loss of bowel and bladder continence, severe dysphagia, and total dependence for feeding and hygienic care, typically culminating in death secondary to aspiration pneumonia, decubitus sepsis, or systemic complications of immobility.

3.3 Clinical Manifestations: Episodic Memory Loss and Global Cognitive Decline

The hallmark clinical presentation of sporadic Alzheimer’s disease is the insidious, gradual onset of profound amnestic episodic memory impairment. This clinical deficit arises directly from early, extensive synaptic dysfunction and neurofibrillary tangle deposition within the perforant path, the entorhinal cortex, and the CA1 subfield of the hippocampus. Patients manifest an inability to encode and consolidate new factual or episodic information into long-term biological storage. Unlike vascular cognitive impairment, wherein memory performance improves substantially with semantic cues or categorical options, Alzheimer’s patients exhibit a true storage consolidation failure: categorical recognition testing yields high false-positive rates and failure to recognize previously presented stimuli, demonstrating that the memory trace was never biologically retained.

As the neuropathological cascade spreads beyond the medial temporal lobes into adjacent parieto-temporal association cortices, additional cognitive domains deteriorate in a stereotypic pattern:

• Language Breakdown (Aphasia): The earliest linguistic manifestation is typically an anomic aphasia, characterized by prominent word-finding pauses, frequent circumlocutions, and the use of generic placeholder terms (e.g., “thing” or “stuff”). As the pathological burden involves the superior temporal gyrus and temporoparietal junctions, language degenerates into a fluent transcortical sensory aphasia, marked by semantic paraphasias, impaired comprehension of complex syntax, and ultimately progress toward global aphasia and mutism.
• Visuospatial and Topographical Disorientation: Disruption of the dorsal and ventral visual processing streams and parietal neocortical degradation impairs mental rotation, spatial mapping, and object location processing. Patients initially become lost while driving in unfamiliar neighborhoods, subsequently losing their bearings in long-inhabited domestic environments, and eventually losing the capacity to recognize familiar faces (prosopagnosia).
• Executive Dysfunction: While less dominant in the earliest stages than episodic amnesia, executive dysregulation emerges as tau pathology invades the prefrontal neocortex. Deficits include impaired financial capacity, inability to sequence complex multi-step tasks (e.g., cooking a complex meal), poor working memory span, and concrete thinking.
• Atypical Alzheimer’s Variants: In a minority of patients, non-amnestic clinical phenotypes emerge based on atypical distributions of tau pathology. These include Posterior Cortical Atrophy (PCA), characterized by predominant visual processing deficits, visual agnosia, Balint’s syndrome, and environmental disorientation; Logopenic Progressive Aphasia (lvPPA), dominated by word-retrieval hesitations and phonological loop deficits; and the Frontal Variant of AD, presenting with prominent early behavioral disinhibition and executive apathy mimicking frontotemporal lobar degeneration.

3.4 Biomarker Profiling and Modern Diagnostic Paradigms

The diagnosis of Alzheimer’s disease has undergone a major paradigm shift, moving from a syndromic, exclusionary diagnosis historically verified only upon post-mortem brain examination to a biologically defined in vivo classification framework. Under the National Institute on Aging and Alzheimer’s Association (NIA-AA) Research Framework, Alzheimer’s disease is defined by the objective presence of specific biomarkers categorized according to the **AT(N)** diagnostic matrix:

• “A” (Amyloid-Beta Pathology): Denotes cortical amyloid-beta deposition, measured in vivo either via Positron Emission Tomography (PET) radiotracers that bind fibrillar amyloid (e.g., [11C]-Pittsburgh Compound B (PiB), [18F]-Florbetapir, [18F]-Florbetaben, and [18F]-Flutemetamol) or via Cerebrospinal Fluid (CSF) analysis demonstrating pathologically reduced levels of the 42-amino-acid peptide (CSF Aβ42) or a decreased CSF Aβ42/Aβ40 ratio. The CSF ratio accounts for inter-individual variability in total amyloid production and exhibits superior diagnostic accuracy over absolute Aβ42 values alone.
• “T” (Tau Pathology): Denotes the presence of hyperphosphorylated tau aggregates, quantified via selective Tau PET ligands (e.g., [18F]-Flortaucipir), which directly map the spatial topography of paired helical filament tau, or via biofluid analysis demonstrating elevated CSF phosphorylated tau at threonine 181 (p-tau181), threonine 217 (p-tau217), or threonine 231 (p-tau231).
• “N” (Neurodegeneration or Neuronal Injury): Denotes non-disease-specific downstream structural, metabolic, and cytoskeletal damage. Biomarkers include structural volumetric MRI demonstrating progressive hippocampal volume loss, entorhinal cortex thinning, and ventricular enlargement; [18F]-Fluorodeoxyglucose (FDG) PET revealing hypometabolism in the temporoparietal association cortices, posterior cingulate, and precuneus; and markedly elevated CSF or plasma neurofilament light chain (NfL), reflecting active axonal disintegration.

The frontier of clinical diagnostics has been transformed by the validation of high-performance blood-based biomarkers. Automated, high-sensitivity immunoassay platforms (such as Single Molecule Array [Simoa] and mass spectrometry) can now measure plasma levels of p-tau181, p-tau217, p-tau231, glial fibrillary acidic protein (GFAP), and the plasma Aβ42/Aβ40 ratio with diagnostic accuracy rivaling traditional CSF assays. In particular, plasma p-tau217 demonstrates an area under the receiver operating characteristic curve (AUC) consistently exceeding 0.90 for discriminating biomarker-confirmed Alzheimer’s pathology from non-Alzheimer’s dementias—including pure vascular dementia—enabling widespread, minimally invasive, and scalable biological diagnostic screening in general clinical populations.

4. Key Differences Between Vascular Dementia and Alzheimer’s Disease

Although both vascular dementia and Alzheimer’s disease produce severe, progressive neurocognitive impairment, they stem from divergent pathophysiological mechanisms and exhibit distinct structural, clinical, and biomarker profiles. The following comparative table delineates the head-to-head differences between these two conditions across primary clinical and pathological parameters:

Diagnostic / Pathological Aspect	Vascular Dementia (VaD)	Alzheimer’s Disease (AD)
Primary Neuropathology	Macrovascular/microvascular ischemic infarcts, lacunes, diffuse white matter rarefaction, arteriolosclerosis, and microhemorrhages.	Extracellular amyloid-beta (Aβ42) senile plaques and intracellular paired helical filament hyperphosphorylated tau neurofibrillary tangles.
Molecular Drivers	Ischemia, hypoxemia, blood-brain barrier disruption, endothelial dysfunction, excitotoxicity, and microvascular thrombosis.	Aberrant amyloid precursor protein (APP) processing via BACE1 and γ-secretase, impaired Aβ clearance, and kinase-driven tau hyperphosphorylation.
Clinical Onset Pattern	Typically abrupt or acute onset following clinical strokes; can be insidious in pure subcortical small vessel disease.	Insidious, subtle, and gradual onset spanning months to years, often unrecognized in earliest phases.
Trajectory of Decline	Stepwise, fluctuating, or discontinuous progression with prolonged plateaus; occasional transient partial recovery.	Continuous, smooth, unremitting, and progressive decline without true functional or cognitive plateaus.
Predominant Cognitive Deficit	Early, prominent executive dysfunction, marked psychomotor slowing, attentional deficits, and impaired cognitive flexibility.	Early, prominent episodic memory loss (anterograde amnesia) affecting acquisition, storage, and delayed recall.
Episodic Memory Profile	Retrieval deficit: Free recall is impaired, but recognition testing and semantic category cueing significantly improve performance.	Encoding/Consolidation deficit: Severe impairment in storage; semantic cueing and recognition testing fail to improve performance.
Early Motor Signs	Frequent and early: Short-stepping or magnetic gait apraxia, focal neurological deficits (hemiparesis, hyperreflexia, Babinski sign), dysarthria.	Absent in early to moderate stages; motor function, gait, and coordination typically remain intact until advanced neocortical stages.
Autonomic & Bulbar Signs	Early urinary urgency, urge incontinence, and pseudobulbar affect (pathological emotional lability).	Autonomic and sphincter disturbances emerge only in late-stage dementia; pseudobulbar affect is rare.
Structural MRI Findings	Extensive confluent white matter hyperintensities (Fazekas 2-3), subcortical lacunar infarcts, cortical territorial infarcts, and microbleeds.	Disproportionate medial temporal lobe atrophy (hippocampus and entorhinal cortex), temporoparietal cortical volume loss.
Fluid Biomarkers (CSF / Plasma)	Normal p-tau (p-tau181/217) and normal Aβ42/Aβ40 ratio; elevated albumin quotient (Qalb) reflecting BBB leakiness; elevated NfL.	Markedly decreased CSF/plasma Aβ42/Aβ40 ratio; markedly elevated CSF and plasma phosphorylated tau (p-tau181, p-tau217); elevated NfL.
Functional PET Imaging	FDG-PET shows asymmetric, patchy, multi-focal subcortical, basal ganglia, and thalamic hypometabolism.	FDG-PET shows symmetric hypometabolism centered in the temporoparietal association cortices, posterior cingulate, and precuneus.
Major Genetic Drivers	Typically polygenic vascular risk; rare monogenic forms include NOTCH3 (CADASIL), HTRA1 (CARASIL), and COL4A1.	Susceptibility: APOE ε4 allele. Deterministic early-onset autosomal dominant mutations: APP, PSEN1, PSEN2.
Primary Therapeutic Goals	Aggressive secondary stroke prevention, blood pressure and lipid optimization, antithrombotic management, functional rehabilitation.	Disease-modifying amyloid clearance, symptomatic cholinergic augmentation, NMDA receptor stabilization, cognitive support.
Approved Medications	No specific FDA-approved disease-modifying agents; off-label use of cholinesterase inhibitors provides limited, modest benefit.	Cholinesterase inhibitors (Donepezil, Galantamine, Rivastigmine), Memantine, anti-amyloid monoclonal antibodies (Lecanemab, Donanemab).

4.1 Etiology, Underlying Neuropathology, and Molecular Drivers

The molecular architectures driving vascular dementia and Alzheimer’s disease represent fundamentally different biological paradigms. Vascular dementia is an extrinsic, secondary consequence of structural vascular breakdown. Its pathology is driven by systemic, macrovascular, or microvascular abnormalities that compromise cerebral blood flow. At the cellular level, the inciting event is focal or widespread tissue ischemia, anoxia, or hemorrhagic disruption. The ensuing cellular death is dictated by failure of oxidative phosphorylation, loss of adenosine triphosphate (ATP), membrane depolarization, calcium toxicity, and enzymatic degradation of cellular membranes through the activation of calpains and caspases.

Conversely, Alzheimer’s disease is an intrinsic, cell-autonomous and non-cell-autonomous proteopathy driven by protein misfolding, aggregate seeding, and trans-synaptic pathological spread. Rather than tissue necrosis caused by vascular occlusions, Alzheimer’s disease is triggered by the neurotoxic properties of intermediate amyloid-beta oligomers and hyperphosphorylated tau assemblies. These pathogenic protein conformations interact directly with cell-surface receptors (e.g., EphA4, cellular prion protein, NMDA receptors), impair long-term potentiation, stimulate pathological microglial activation, destabilize the axonal cytoskeleton, and induce progressive synaptic dismantling. While vascular dementia is essentially a disease of perfusion failure and structural parenchymal injury, Alzheimer’s disease is an unremitting neurodegenerative protein misfolding cascade that slowly destroys neural circuits from within.

Genetic architectures further underscore this distinction. The genetic basis of sporadic Alzheimer’s disease is heavily influenced by the APOE gene on chromosome 19, where inheritance of the ε4 allele increases the risk of developing the disease in a gene-dose-dependent manner by impairing amyloid clearance and promoting lipid dysregulation. Familial, early-onset autosomal dominant Alzheimer’s disease is directly driven by deterministic missense mutations in the APP, PSEN1, or PSEN2 genes, which directly alter the enzymatic cleavage profile of gamma-secretase to favor longer, aggregation-prone Aβ42 peptides. In contrast, common vascular dementia does not possess a primary, single-gene susceptibility locus equivalent to APOE ε4; instead, it is influenced by polygenic traits that regulate vascular physiology, including blood pressure regulation, endothelial nitric oxide synthase activity, and systemic lipid metabolism. Rare monogenic forms of vascular dementia exist—such as Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL), caused by stereotyped cysteine-altering mutations in the NOTCH3 gene on chromosome 19—yet these cases are defined by primary vascular wall degeneration (granular osmiophilic material deposition) entirely distinct from amyloid-tau cascades.

4.2 Onset Dynamics and Trajectory of Cognitive Decline

The temporal dynamics of disease evolution provide a clear clinical discriminator between vascular dementia and Alzheimer’s disease. Classical vascular dementia typically begins with an abrupt onset, wherein an individual experiences an acute, identifiable functional or cognitive drop following a stroke or a series of microvascular infarcts. The subsequent trajectory exhibits a stepwise or fluctuating progression: cognitive function drops acutely following each ischemic threshold, stabilized by periods of clinical plateaus during which compensatory neuronal networks may facilitate modest functional recovery, before a subsequent ischemic insult prompts another cognitive drop. While this stepwise pattern may be less pronounced in pure subcortical ischemic vascular dementia (where slow microvascular rarefaction can mimic a gradual decline), sudden deviations from baseline, fluctuating alertness, and transient functional drops remain characteristic of vascular disease.

In marked contrast, Alzheimer’s disease exhibits an insidious, gradual, and uninterrupted clinical trajectory. Because the underlying biological accumulation of amyloid-beta plaques and neurofibrillary tangles develops continuously over decades, the transition from normal cognition to subjective cognitive decline, amnestic mild cognitive impairment, and overt dementia occurs smoothly without identifiable points of acute onset. Patients, family members, and clinicians are often unable to identify the precise month or season when cognitive impairment began. Furthermore, the rate of progression in Alzheimer’s disease is characterized by an unremitting, continuous decline without prolonged, multi-year stable plateaus. Once clinical dementia is established, patients lose an average of 2 to 4 points per year on the Mini-Mental State Examination (MMSE), reflecting ongoing, uninterrupted neocortical synaptic degradation and neuronal loss.

A critical clinical consideration is the response to physiological stressors. While Alzheimer’s patients certainly deteriorate during systemic infections, metabolic disturbances, or hospitalizations (delirium superimposed on dementia), they return toward their baseline neurodegenerative trajectory once the delirium resolves. In patients with vascular dementia, however, a systemic hemodynamic drop—such as an episode of severe orthostatic hypotension, cardiac arrhythmia, or intraoperative hypotension—can permanently convert borderline subcortical white matter ischemia into complete, irreversible tissue infarction, altering the baseline cognitive plateau permanently.

4.3 Neuropsychological Profiles: Executive Function vs. Episodic Memory

Neuropsychological evaluation provides one of the most reliable clinical differentiators between vascular dementia and Alzheimer’s disease, provided testing evaluates specific cognitive sub-domains rather than relying solely on global screening tools. The core neuropsychological divergence lies in the double dissociation between fronto-subcortical executive control and medial temporal episodic memory storage.

Vascular cognitive impairment is predominantly an executive-slowing disorder. The interruption of fronto-striato-thalamic circuits leads to early, profound impairments on tests of mental flexibility, response inhibition, planning, and abstract reasoning. Patients perform poorly on the Trail Making Test Part B, the Stroop Color-Word Interference Test, the Wisconsin Card Sorting Test, and digit span backward tasks. Concurrently, psychomotor processing speed (measured via the Symbol Digit Modalities Test or Digit Symbol Substitution) is markedly diminished. When evaluating memory, individuals with vascular dementia frequently show impaired free delayed recall; however, their performance improves significantly when categorical clues, semantic prompts, or multiple-choice recognition options are presented. This preservation demonstrates that the hippocampal-entorhinal memory consolidation mechanism remains functional, with deficits primarily reflecting impaired frontal retrieval and search strategies.

Alzheimer’s disease, conversely, is predominantly an amnesic-consolidation disorder. Pathological involvement of the entorhinal cortex, perforant path, and hippocampus destroys the biological machinery required to consolidate new episodic information into long-term neocortical networks. On neuropsychological testing (such as the Free and Cued Selective Reminding Test [FCSRT] or the California Verbal Learning Test [CVLT]), Alzheimer’s patients exhibit rapid forgetting rates, abnormal learning curves over repeated trials, and a high frequency of intrusive errors. Crucially, neither semantic cues nor recognition paradigms normalize their memory performance. Because the memory trace was never consolidated within the hippocampal formation, cues provide no utility, and recognition testing frequently results in false identifications.

Linguistic profiles also diverge substantially between the two conditions. In Alzheimer’s disease, semantic memory deteriorates early; patients display prominent naming deficits on the Boston Naming Test, alongside rapid degradation of semantic category fluency (e.g., naming animals in 60 seconds) that is disproportionately worse than phonemic letter fluency (e.g., naming words beginning with the letter “F”). In vascular dementia, phonemic fluency is typically more severely compromised than semantic category fluency, directly reflecting impaired executive search and retrieval mechanics governed by frontal-subcortical circuits rather than a primary dissolution of the semantic storage lexicon.

4.4 Neuroimaging and Fluid Biomarker Distinctions

The definitive in vivo separation of vascular dementia and Alzheimer’s disease increasingly relies upon objective structural, molecular, and fluid biomarker signatures. Structural neuroimaging via brain MRI remains indispensable. In vascular dementia, MRI sequences display a heavy burden of ischemic and microvascular pathology. FLAIR and T2-weighted sequences reveal extensive, confluent periventricular and deep white matter hyperintensities (Fazekas grades 2 to 3), multiple subcortical lacunar infarcts, and sometimes prior territorial cortical strokes. Gradient echo (T2*-GRE) and susceptibility-weighted imaging (SWI) sequences reveal cerebral microbleeds in deep subcortical structures (thalamus, basal ganglia, internal capsule) indicative of hypertensive vasculopathy, or in lobar distributions indicative of cerebral amyloid angiopathy. Cortical atrophy in vascular dementia is typically secondary, diffuse, or anatomically correlated with vascular supply zones.

In contrast, structural MRI in early-to-moderate Alzheimer’s disease demonstrates a disproportionate, symmetric or asymmetric atrophy of the medial temporal lobes, with pronounced volume loss in the hippocampus and entorhinal cortex, accompanied by enlargement of the temporal horns of the lateral ventricles. These changes are quantified visually via the Scheltens Medial Temporal Lobe Atrophy (MTA) scale. While older Alzheimer’s patients frequently exhibit age-related white matter hyperintensities, these lesions are generally milder, punctate, and disproportionately less severe than the profound degree of medial temporal atrophy present on the scan.

Molecular and biofluid biomarkers provide unambiguous distinction. On 18F-FDG PET, Alzheimer’s disease produces a stereotypic pattern of bilateral, symmetric hypometabolism involving the temporoparietal association cortices, the precuneus, and the posterior cingulate cortex, with relative sparing of the primary visual cortex, motor strips, and basal ganglia. Vascular dementia produces an asymmetric, patchy, multi-focal pattern of hypometabolism involving the subcortical gray matter, thalamus, and distributed frontal and cortical regions matching underlying vascular insults. Fluid biomarker profiles—obtained via cerebrospinal fluid lumbar puncture or validated ultra-sensitive plasma assays—exhibit clear profiles:

• Alzheimer’s Profile: Markedly elevated phosphorylated tau (p-tau181, p-tau217, p-tau231), elevated total tau (t-tau), and markedly decreased Aβ42 or Aβ42/Aβ40 ratio. Tau PET imaging reveals cortical ligand uptake matching Braak stages.
• Pure Vascular Profile: Normal phosphorylated tau levels (p-tau181, p-tau217), normal Aβ42/Aβ40 ratios, and non-specific elevations in neurofilament light chain (NfL), reflecting active axonal shearing and ischemic breakdown. The CSF-to-serum albumin quotient (Qalb) is frequently elevated, serving as a biological indicator of compromised blood-brain barrier integrity.

4.5 Pharmacological Interventions and Therapeutic Goals

Therapeutic management strategies diverge fundamentally between these two disorders, reflecting their different underlying pathophysiologies. The management of vascular dementia centers entirely upon aggressive, targeted secondary cerebrovascular prevention. The primary therapeutic goal is the prevention of subsequent ischemic or hemorrhagic strokes, stabilization of systemic hemodynamics, and preservation of remaining functional neural tissue. Interventions include:

• Secondary Stroke Prophylaxis: Antiplatelet therapy (e.g., aspirin, clopidogrel) for non-cardioembolic disease, or direct oral anticoagulants (DOACs, such as apixaban or dabigatran) for patients with concurrent non-valvular atrial fibrillation.
• Hemodynamic Optimization: Strict blood pressure control utilizing angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or calcium channel blockers. Clinical trial evidence confirms that lowering systolic blood pressure mitigates white matter lesion accrual and preserves executive processing.
• Lipid-Lowering and Metabolic Control: High-intensity statin therapy (e.g., atorvastatin 80 mg) to achieve plaque stabilization and anti-inflammatory endothelial effects, alongside targeted glycemic control for type 2 diabetes.
• Symptomatic Cognitive Pharmacotherapy: There are no specific medications approved by regulatory agencies (such as the US FDA or EMA) specifically for vascular dementia. While acetylcholinesterase inhibitors (donepezil, galantamine) and the NMDA receptor antagonist memantine are occasionally prescribed off-label for vascular dementia, randomized controlled trials demonstrate only marginal, clinically modest improvements in cognitive testing scores without substantial impacts on global functional preservation.

In stark contrast, the therapeutic landscape for Alzheimer’s disease focuses primarily on disease-modifying proteopathic clearance and symptomatic neurochemical augmentation. Management is structured around two pharmacological categories:

• Symptomatic Neurotransmitter Augmentation: Acetylcholinesterase inhibitors (Donepezil, Galantamine, Rivastigmine) compensate for the degeneration of cholinergic basal forebrain neurons by elevating synaptic acetylcholine levels within the neocortex and hippocampus, offering stabilized cognition and functional preservation over 6 to 12 months. In moderate to severe stages, Memantine, an uncompetitive low-affinity NMDA receptor antagonist, is introduced to mitigate excitotoxic, pathological tonic glutamate activation without disrupting physiological neurotransmission.
• Disease-Modifying Anti-Amyloid Monoclonal Antibodies: The modern therapeutic paradigm for Alzheimer’s disease has been fundamentally altered by humanized IgG1 monoclonal antibodies directed against aggregated amyloid-beta. Agents such as Lecanemab (which selectively targets soluble amyloid protofibrils) and Donanemab (which targets N-terminally truncated pyroglutamate amyloid plaques) have demonstrated statistically significant reductions in neocortical amyloid burdens on PET, translating to a 27 to 35 percent slowing of clinical cognitive and functional decline over 18 months in early symptomatic patients.

Crucially, anti-amyloid monoclonal antibodies are completely ineffective for pure vascular dementia and are strictly contraindicated in conditions characterized by widespread cerebral hemorrhage or significant coagulopathy. Furthermore, patients treated with anti-amyloid therapies require rigorous safety surveillance via specialized MRI protocols to monitor for Amyloid-Related Imaging Abnormalities (ARIA), including ARIA-E (vasogenic parenchymal edema) and ARIA-H (microhemorrhages and superficial siderosis)—pathologies that directly intersect with cerebrovascular integrity.

5. Shared Features, Comorbidities, and Mixed Dementia

5.1 Shared Cardiovascular Risk Factors and Synergistic Pathophysiology

While vascular dementia and Alzheimer’s disease occupy distinct conceptual poles within neurocognitive diagnostics, they are unified by a complex web of shared cardiovascular, metabolic, and lifestyle risk factors. Large-scale epidemiological cohorts—including the Framingham Heart Study, the Rotterdam Study, and the Atherosclerosis Risk in Communities (ARIC) study—have confirmed that midlife hypertension, cigarette smoking, type 2 diabetes mellitus, hyperlipidemia, abdominal adiposity, and physical inactivity independently increase the relative risk for developing not only vascular dementia, but also clinically diagnosed Alzheimer’s disease.

The biological mechanisms linking vascular risk factors to Alzheimer’s pathology are described by the “two-hit” vascular hypothesis of Alzheimer’s disease. According to this model, vascular risk factors (such as chronic hypertension or hypercholesterolemia) induce primary cerebrovascular damage (Hit 1), causing microvascular endothelial dysfunction, basement membrane thickening, pericyte degeneration, and reduced resting cerebral blood flow. This chronic hypoperfusion and blood-brain barrier disruption compromises the transport mechanics responsible for clearing amyloid-beta out of the brain parenchyma. Receptors such as the low-density lipoprotein receptor-related protein 1 (LRP1) fail to effectively export Aβ into the circulation, while the receptor for advanced glycation endproducts (RAGE) imports circulating Aβ back across the compromised BBB, promoting parenchymal and perivascular amyloid accumulation (Hit 2).

Furthermore, chronic microvascular ischemia directly upregulates the expression and activity of BACE1 (beta-secretase), accelerating the cleavage of APP toward pathogenic Aβ42 generation. In parallel, parenchymal amyloid-beta oligomers induce perivascular inflammation, trigger reactive oxygen species generation via NADPH oxidase, and promote the production of endothelin-1, a potent vasoconstrictor. This cascade further constricts microvessels, exacerbating focal cerebral hypoperfusion and establishing a self-amplifying, destructive cycle wherein vascular injury accelerates amyloid-tau proteopathy, and advancing proteopathy destroys the microvasculature.

5.2 Convergence of Behavioral and Psychological Symptoms of Dementia (BPSD)

As parenchymal damage, neural disconnection, and neurotransmitter exhaustion advance, both vascular dementia and Alzheimer’s disease converge upon a common spectrum of Behavioral and Psychological Symptoms of Dementia (BPSD). These neuropsychiatric manifestations represent a major clinical driver of caregiver distress, early institutionalization, and accelerated functional mortality. While the core behavioral symptoms overlap, their early neuroanatomical localization and phenomenology frequently diverge:

• Apathy and Abulia: Apathy—characterized by diminished goal-directed behavior, flattened emotional resonance, and profound lack of initiative—is remarkably prevalent in subcortical ischemic vascular dementia, occurring in up to 70 to 80 percent of patients. Its early manifestation is directly attributable to the structural disruption of frontostriatal pathways linking the anterior cingulate cortex, the dorsolateral prefrontal cortex, and the caudate nucleus. In Alzheimer’s disease, apathy typically manifests later, tracking the invasion of tau pathology and synaptic loss into the frontal neocortex.
• Depression: Depressive symptoms and major depressive episodes are significantly more common and severe in vascular dementia than in early-stage Alzheimer’s disease. Often termed “vascular depression,” this syndrome is characterized by prominent psychomotor slowing, executive dysfunction, lethargy, and poor insight, exhibiting relative resistance to conventional serotonergic antidepressants due to structural ischemic white matter tract disruption.
• Agitation, Irritability, and Wandering: As cortical control over limbic structures weakens, both patient populations experience severe agitation, restlessness, pacing, and sleep-wake cycle disturbances. In Alzheimer’s disease, agitation often manifests as “sundowning”—a marked clinical deterioration occurring during late afternoon and early evening hours, driven by neurodegeneration of the suprachiasmatic nucleus within the hypothalamus and circadian disruption.
• Psychotic Symptoms (Delusions and Hallucinations): Psychotic features emerge in 30 to 50 percent of patients in the moderate to severe stages of both disorders. In Alzheimer’s disease, delusions are frequently persecutory, memory-based, or misidentificatory (e.g., the belief that deceased relatives are still alive, that caregivers are stealing misplaced belongings, or that their home is not their real home). Vascular dementia may feature similar delusions, but visual hallucinations can also emerge acutely following focal ischemic strokes within the posterior visual pathways or the thalamus (peduncular hallucinosis).

5.3 Mixed Dementia: The Pathological Coexistence of AD and VaD

The strict binary distinction between “pure” Alzheimer’s disease and “pure” vascular dementia is, in many elderly individuals, a clinical oversimplification. Post-mortem clinicopathological studies have revealed that pure forms of either disorder represent the minority in nonagenarians and octogenarians. Instead, the most common pathological diagnosis observed in community-dwelling older adults dying with dementia is **Mixed Dementia**—defined as the simultaneous coexistence of Alzheimer’s neuropathological hallmarks (amyloid plaques and neurofibrillary tangles) and significant cerebrovascular lesions (macroscopic territorial strokes, multiple lacunes, or severe arteriolosclerotic leukoaraiosis).

Autopsy series, such as those from the Religious Orders Study and Memory and Aging Project (ROSMAP), demonstrate that between 30 and 50 percent of individuals clinically diagnosed with probable Alzheimer’s disease exhibit significant, concurrent cerebrovascular pathology upon post-mortem brain examination. Importantly, these studies demonstrate an additive or synergistic effect: the presence of subcortical lacunar infarcts or severe white matter ischemic disease significantly lowers the biological threshold of Alzheimer’s pathology required to cause clinical dementia. An individual with a modest, subclinical burden of amyloid and tau pathology who would otherwise remain cognitively asymptomatic can be precipitated into overt dementia by the addition of two or three small subcortical lacunes. Conversely, extensive cerebrovascular damage diminishes the brain’s cognitive reserve, leaving neural networks fragile in the face of subsequent neurodegenerative protein deposition.

Clinically, mixed dementia presents with an intermediate, heterogeneous phenotype. A patient might exhibit an insidious, gradual memory decline characteristic of Alzheimer’s, but concurrently display prominent executive slowing, a wide-based gait, and sudden stepwise functional worsening following microvascular ischemic events. Neuroimaging in mixed dementia demonstrates both significant medial temporal lobe atrophy and extensive white matter hyperintensities (Fazekas grade 3) or multiple lacunes. Recognizing mixed dementia is clinically critical because it requires a comprehensive management approach: combining symptomatic anti-Alzheimer’s pharmacotherapy with aggressive, secondary vascular risk reduction.

6. Clinical Decision-Making, Differential Diagnosis, and Care Pathways

6.1 Stepwise Diagnostic Algorithms in Clinical Practice

Navigating the differential diagnosis between vascular dementia, Alzheimer’s disease, and mixed presentations requires a structured, multi-tiered clinical evaluation algorithm. Relying on an unstructured interview or a brief global screening test often leads to misdiagnosis. Clinicians should implement the following stepwise diagnostic pathway:

1. Comprehensive Chronological History via Collateral Informant: The clinical evaluation must begin with an extensive interview of a reliable family member or caregiver. The clinician must establish the precise onset dynamics (abrupt vs. insidious), the temporal progression profile (stepwise/fluctuating vs. smoothly progressive), and the earliest functional domains compromised (driving and planning vs. episodic forgetfulness and repeating questions). A detailed vascular history must be documented, including transient ischemic attacks (TIAs), overt strokes, poorly controlled hypertension, diabetes, hyperlipidemia, and smoking history.
2. Targeted Cognitive Assessment: Brief global screening tools like the Mini-Mental State Examination (MMSE) are notoriously insensitive to subcortical vascular executive dysfunction. Clinicians should employ the Montreal Cognitive Assessment (MoCA), which incorporates robust tests of executive function (clock drawing, trails, abstraction), processing speed, and multiple-choice cued memory paradigms. For detailed evaluations, formal neuropsychological assessment should measure the dissociation between delayed free recall and cued recognition, alongside processing speed metrics (Trail Making Tests A & B, Digit Symbol Coding).
3. Quantitative Ischemia Scoring: Clinicians should calculate the validated Hachinski Ischemic Score (HIS). The score assigns points based on historical and clinical features:
   • Abrupt onset (2 points)
   • Stepwise deterioration (1 point)
   • Fluctuating course (2 points)
   • Nocturnal confusion (1 point)
   • Relative preservation of personality (1 point)
   • Depression (1 point)
   • Somatic complaints (1 point)
   • Emotional incontinence (1 point)
   • History of hypertension (1 point)
   • History of strokes (2 points)
   • Associated focal neurological symptoms (2 points)
   • Focal neurological signs (2 points)

   A score of 4 or less is highly sensitive for primary Alzheimer’s disease, a score of 5 or 6 suggests a mixed presentation, and a score of 7 or greater indicates primary vascular dementia.

4. Detailed Neurological Examination: Evaluation should focus on identifying subtle lateralized deficits (focal weakness, asymmetric hyperreflexia, pronator drift, unilateral extensor plantar responses), extrapyramidal features (short-stepping gait, axial rigidity), pseudobulbar affect, and frontal release signs (palmomental, grasp, and snout reflexes).
5. High-Resolution Structural Neuroimaging: Brain MRI without contrast, utilizing high-field 3T acquisition, represents the mandatory structural standard. Protocol sequences must include 3D volumetric T1-weighted, T2-weighted, FLAIR, DWI, and T2*-GRE or SWI. Clinicians must systematically quantify the Scheltens Medial Temporal Lobe Atrophy (MTA) score (graded 0 to 4) and the Fazekas scale for white matter hyperintensities (graded 0 to 3), noting the presence, size, and location of any lacunes, territorial strokes, or cerebral microbleeds.
6. Molecular Biomarker Clarification: In ambiguous presentations, younger-onset cases, or when anti-amyloid monoclonal antibody therapy is under consideration, clinicians should order fluid or PET biomarkers. A plasma p-tau217 assay, CSF Aβ42/Aβ40 ratio with p-tau, or an amyloid/tau PET scan provides biological verification of Alzheimer’s pathology, confirming or excluding an active neurodegenerative proteopathy.

6.2 Risk Stratification and Tailored Prevention Strategies

Once diagnostic stratification is established, preventative and risk-modifying strategies must be tailored to the patient’s individual pathophysiological profile. For patients diagnosed with vascular dementia or significant vascular cognitive impairment, secondary prevention is the cornerstone of clinical management:

• Blood Pressure Targets: The landmark Systolic Blood Pressure Intervention Trial – Memory and Brain in Aging (SPRINT-MIND) demonstrated that intensive systolic blood pressure lowering (target <120 mmHg) significantly reduced the incidence of Mild Cognitive Impairment and attenuated the rate of white matter lesion accrual compared to standard targets (<140 mmHg). In established vascular dementia, consensus guidelines recommend maintaining blood pressure below 130/80 mmHg, avoiding excessive diastolic drops (<60 mmHg) that could induce cerebral hypoperfusion across stenotic microvessels.
• Antithrombotic Strategies: Antiplatelet monotherapy (Aspirin 81 mg daily or Clopidogrel 75 mg daily) is indicated for patients with non-cardioembolic vascular dementia and history of atherothrombotic disease. In patients with non-valvular atrial fibrillation, therapeutic anticoagulation with Direct Oral Anticoagulants (DOACs) reduces the annual risk of recurrent embolic strokes and associated cognitive decline by over 60 percent. However, in patients displaying extensive strictly lobar microbleeds suggestive of severe cerebral amyloid angiopathy, the risks of symptomatic intracerebral hemorrhage must be balanced against systemic thromboembolic risks.
• Metabolic and Lifestyle Interventions: Optimization of glycemic control in type 2 diabetes (aiming for HbA1c between 7.0 and 8.0 percent to prevent hypoglycemia-induced neuronal stress), smoking cessation, adoption of a Mediterranean or MIND (Mediterranean-DASH Intervention for Neurodegenerative Delay) diet, and regular structured aerobic physical activity (minimum 150 minutes per week) confer neurovascular protection. Regular exercise enhances endothelial nitric oxide bioavailability, reduces systemic inflammation, and promotes the release of brain-derived neurotrophic factor (BDNF).

6.3 Multidisciplinary Care Planning and Prognostic Considerations

Caring for individuals with either vascular dementia or Alzheimer’s disease requires an integrated, multidisciplinary care model spanning neurology, primary care, neuropsychology, physical and occupational therapy, speech-language pathology, social work, and palliative medicine. Prognostic expectations differ between the two conditions:

The prognosis of pure vascular dementia is heavily tied to systemic cardiovascular and cerebrovascular events. The median survival from diagnosis ranges between 3 and 7 years, with cardiovascular disease, recurrent disabling stroke, and acute myocardial infarction representing the primary causes of death. Because progression can be arrested or substantially slowed if subsequent vascular events are prevented, effective vascular control can preserve functional plateaus. Comprehensive physical and occupational therapy plays an essential role in vascular dementia, assisting patients in relearning motor routines, adapting to focal gait deficits, and utilizing assistive ambulation devices to prevent falls and hip fractures.

In contrast, the prognosis of Alzheimer’s disease is characterized by a gradual neurodegenerative decline. The median survival from clinical diagnosis ranges from 7 to 12 years. Functional deterioration follows a predictable course: patients gradually lose their ability to complete instrumental activities of daily living, followed by basic self-care tasks. As the disease advances into the terminal phase, swallowing coordination fails, leading to progressive dysphagia, cachexia, and high vulnerability to aspiration pneumonia, which represents the direct cause of death in over 60 percent of patients.

Advance care planning, including establishing medical durable power of attorney, completing living wills, and discussing preferences regarding artificial nutrition and hydration (e.g., the avoidance of percutaneous endoscopic gastrostomy [PEG] tubes in end-stage dementia), must be initiated early in both disease courses while the patient retains decision-making capacity. Legal and financial planning should be structured proactively to prevent exploitation and ensure continuity of patient-centered care. Caregiver education and support programs, respite services, and local memory care resources are critical to mitigate caregiver burnout and depression.

7. Frequently Asked Questions

7.1 Can a Patient Have Both Alzheimer’s Disease and Vascular Dementia Simultaneously?

Yes. When an individual displays the pathological hallmarks and clinical features of both disorders, the diagnosis is designated as Mixed Dementia. Rather than being rare, this clinical scenario is exceptionally common, particularly among individuals over the age of 80. Autopsy studies confirm that over 30 to 50 percent of older individuals clinically diagnosed with probable Alzheimer’s disease have concurrent cerebrovascular lesions, including microscopic lacunes, white matter ischemia, or prior infarcts. The two pathologies act synergistically: cerebrovascular lesions lower the biological threshold for amyloid-beta and tau proteopathies to manifest clinically, meaning a patient with mild, otherwise subclinical Alzheimer’s changes can experience cognitive decline when vascular injury occurs. Managing mixed dementia requires addressing both processes simultaneously: providing neurodegenerative symptomatic support (e.g., cholinesterase inhibitors, memantine) alongside aggressive cardiovascular risk management (blood pressure optimization, antiplatelets, lipid management).

7.2 How Does the Progression Rate Differ Between Vascular Dementia and Alzheimer’s?

The progression dynamics typically exhibit different clinical trajectories. Alzheimer’s disease follows an insidious, continuous, and unremitting neurodegenerative decline. Cognitive, linguistic, and functional capabilities decline gradually over years without prolonged periods of spontaneous recovery or true multi-year plateaus. In contrast, classic multi-infarct vascular dementia follows an abrupt, stepwise trajectory: cognitive decline occurs in distinct drops corresponding to acute or covert ischemic strokes, interspersed with periods of stability or modest recovery as surrounding brain regions adapt. However, in subcortical ischemic vascular dementia (caused by chronic small vessel disease), the progression can sometimes be more gradual and continuous, mimicking Alzheimer’s disease. Effective secondary stroke prevention and blood pressure management can slow or halt further stepwise decline in vascular dementia, whereas Alzheimer’s disease continues its gradual neurodegenerative course unless treated with targeted disease-modifying therapies.

7.3 Are Alzheimer’s Medications Effective in Treating Vascular Dementia?

Medications specifically developed and approved for Alzheimer’s disease have limited utility in pure vascular dementia. Cholinesterase inhibitors (donepezil, galantamine, rivastigmine) and the NMDA receptor antagonist memantine have been evaluated in large-scale clinical trials for vascular cognitive impairment. While these trials showed small, statistically significant improvements on cognitive test scores, these improvements rarely translated into clinically meaningful changes in global function or independence in activities of daily living. Consequently, these medications are not approved by major regulatory bodies (such as the US FDA or EMA) for the treatment of pure vascular dementia, though they are frequently prescribed off-label. Disease-modifying anti-amyloid monoclonal antibodies (such as lecanemab and donanemab) are completely ineffective for pure vascular dementia and are strictly contraindicated. The cornerstone of vascular dementia management remains secondary vascular prevention, stroke prophylaxis, and targeted rehabilitation.

7.4 Can Controlling Blood Pressure Prevent Vascular Dementia or Alzheimer’s?

Yes. Robust clinical trial data and longitudinal epidemiological studies confirm that aggressive blood pressure management represents one of the most effective interventions for preserving cognitive function. The landmark SPRINT-MIND clinical trial demonstrated that intensive systolic blood pressure lowering to a target below 120 mmHg resulted in a 19 percent relative risk reduction in the incidence of Mild Cognitive Impairment (MCI) and a 15 percent reduction in the combined outcome of MCI and probable dementia. Blood pressure management directly preserves the integrity of deep penetrating cerebral arterioles, preventing lipohyalinosis, reducing lacunar strokes, and limiting the accrual of confluent white matter hyperintensities. Furthermore, by maintaining blood-brain barrier integrity and cerebral capillary perfusion, hypertension management supports the brain’s glymphatic waste-clearance pathways, aiding the clearance of toxic proteopathic peptides and conferring clinical protection against both vascular dementia and Alzheimer’s disease.

8. Conclusion: Synthesizing the Clinical Divide and Future Directions

8.1 Summary of Core Pathological and Symptomatic Distinctions

The clinical and pathological differentiation between vascular dementia and Alzheimer’s disease is an essential foundation of modern neurogeriatric medicine. While both disorders produce major neurocognitive impairment, they stem from fundamentally distinct etiologies. Alzheimer’s disease is an intrinsic, neurodegenerative proteopathy initiated by amyloid-beta oligomerization and propelled by hyperphosphorylated tau neurofibrillary tangles, manifesting clinically with early, profound amnesic episodic storage failure, anomia, and visuospatial disorientation, with preserved motor function until advanced stages. Vascular dementia is an ischemic or hemorrhagic disorder driven by large-vessel atherothrombosis, cardioembolism, or cerebral small vessel arteriolosclerosis, manifesting clinically with abrupt or stepwise trajectories, prominent executive dysfunction, marked psychomotor slowing, retrieval-based memory deficits, and early motor and autonomic signs (such as gait apraxia, urinary urgency, and pseudobulbar affect).

Diagnostic evaluation has evolved beyond purely observational phenomenology. Clinicians now have access to high-resolution structural MRI to quantify small vessel ischemic lesions versus medial temporal lobe atrophy, validated clinical scoring instruments like the Hachinski Ischemic Score, and advanced fluid and molecular biomarkers (including CSF and plasma p-tau217, the Aβ42/Aβ40 ratio, and tau/amyloid PET) that permit biological diagnostic accuracy during life. These diagnostic distinctions are critical because therapeutic pathways diverge: vascular dementia management centers on aggressive secondary stroke prevention, blood pressure control, and physical rehabilitation, whereas Alzheimer’s disease management relies on symptomatic cholinergic augmentation and targeted anti-amyloid disease-modifying therapies.

8.2 The Evolving Paradigm of Biomarker-Driven Precision Neurology

The clinical approach to neurocognitive disorders is undergoing a profound paradigm shift driven by fluid biomarkers, molecular neuroimaging, and artificial intelligence. The validation of high-performance blood-based assays—most notably plasma p-tau217 and the plasma Aβ42/Aβ40 ratio—is transitioning the diagnostic workup from specialized academic medical centers into accessible primary care environments. These blood tests allow clinicians to determine, from a routine peripheral phlebotomy draw, whether an individual’s cognitive decline is driven by an underlying Alzheimer’s proteopathy, effectively confirming or excluding Alzheimer’s pathology even in the presence of extensive comorbid cerebrovascular white matter changes.

Concurrently, advances in structural and functional neuroimaging are refining differential diagnostic capacity. Ultra-high-field 7.0-Tesla MRI allows direct in vivo visualization of lenticulostriate vessel walls, cerebral microinfarcts measuring under 1 millimeter, and subtle disruption of cortical laminar architecture. Machine learning and deep artificial intelligence algorithms applied to standard volumetric T1 and FLAIR sequences can decouple age-related cortical thinning from vascular leukoaraiosis, providing automated, standardized volumetric assessments of hippocampal atrophy and vascular lesion loads. In molecular imaging, next-generation PET radiotracers are expanding beyond amyloid and tau to directly quantify synaptic density (via SV2A ligands), microglial-mediated neuroinflammation (via TSPO tracers), and blood-brain barrier permeability, paving the way for multi-targeted precision neurology.

8.3 Final Perspectives on Patient-Centered Clinical Management

As the biomedical understanding of neurocognitive disorders advances, the ultimate objective of diagnostic differentiation remains centered on the patient: optimizing quality of life, preserving functional autonomy, and delivering personalized care. Establishing an accurate, timely, and biomarker-verified diagnosis provides immediate clarity for patients and their families, validating symptoms and opening pathways to targeted treatments, clinical trial enrollment, and appropriate support resources.

Furthermore, recognizing the frequent overlap of vascular brain injury and neurodegenerative pathology reinforces the universal clinical value of vascular prevention across the adult lifespan. Aggressive management of midlife blood pressure, physical exercise, smoking cessation, and metabolic control represents our most accessible and scalable defense against cognitive decline—reducing the incidence of primary vascular dementia while lowering the likelihood that subclinical Alzheimer’s pathology will cross the threshold into overt clinical dementia. Moving forward, clinical care must combine precision biomarker-driven diagnostics with comprehensive, compassionate, multidisciplinary support that honors the functional autonomy and dignity of every individual experiencing cognitive decline.

References

• Alzheimer, A., Stelzmann, R. A., Schnitzlein, H. N., & Murtagh, F. R. (1995). An English translation of Alzheimer’s 1907 paper, “Über eine eigenartige Erkrankung der Hirnrinde”. Clinical Anatomy, 8(6), 429–431. https://doi.org/10.1002/ca.980080612
• Braak, H., & Braak, E. (1991). Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica, 82(4), 239–259. https://doi.org/10.1007/BF00308809
• Hachinski, V. C., Iliff, L. D., Zilhka, E., Du Boulay, G. H., McAllister, V. L., Marshall, J., Russell, R. W., & Symon, L. (1975). Cerebral blood flow in dementia. Archives of Neurology, 32(9), 632–637. https://doi.org/10.1001/archneur.1975.00490510088009
• Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., Liu, E., Molinuevo, J. L., Montine, T., Phelps, C., Rankin, K. P., Rowe, C. C., Scheltens, P., Siemers, E., Snyder, H. M., & Sperling, R. (2018). NIA-AA Research Framework: Toward an unbiased biological definition of Alzheimer’s disease. Alzheimer’s & Dementia, 14(4), 535–562. https://doi.org/10.1016/j.jalz.2018.02.018
• Pantoni, L. (2010). Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. The Lancet Neurology, 9(7), 689–701. https://doi.org/10.1016/S1474-4422(10)70104-6
• Roman, G. C., Tatemichi, T. K., Erkinjuntti, T., Cummings, J. L., Masdeu, J. C., Garcia, J. H., Amaducci, L., Orgogozo, J. M., Brun, A., & Hofman, A. (1993). Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology, 43(2), 250–260. https://doi.org/10.1212/wnl.43.2.250
• Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021). Alzheimer’s disease. The Lancet, 397(10284), 1577–1590. https://doi.org/10.1016/S0140-6736(20)32205-4
• Skrobot, O. A., O’Brien, J., Black, S., Chen, C., DeCarli, C., Erkinjuntti, T., Ford, G. A., Kalaria, R. N., Pantoni, L., Pantoni, M., Rockwood, K., Sachdev, P., & Dichgans, M. (2017). The Vascular Impairment of Cognition Classification Consensus Study. Alzheimer’s & Dementia, 14(3), 280–292. https://doi.org/10.1016/j.jalz.2017.09.007
• SPRINT MIND Investigators for the SPRINT Research Group. (2019). Effect of intensive vs standard blood pressure control on probable dementia: A randomized clinical trial. JAMA, 321(6), 553–561. https://doi.org/10.1001/jama.2018.21442
• van der Flier, W. M., Skoog, I., Schneider, J. A., Pantoni, L., Mok, V. C., Chen, C. L. H., & Scheltens, P. (2018). Vascular cognitive impairment. Nature Reviews Disease Primers, 4(1), 18003. https://doi.org/10.1038/nrdp.2018.3
• Wardlaw, J. M., Smith, E. E., Biessels, G. J., Cordonnier, C., Fazekas, F., Frayne, R., Lindley, R. I., O’Brien, J. T., Barkhof, F., Benavente, O. R., Black, S. E., Brayne, C., Breteler, M., Chabriat, H., DeCarli, C., Dichgans, M., Doubal, F., Duering, M., Fox, N. C., … & STandards for ReportIng Vascular changes on nEuroimaging (STRIVE). (2013). Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. The Lancet Neurology, 12(8), 822–838. https://doi.org/10.1016/S1474-4422(13)70124-8
• Zlokovic, B. V. (2011). Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nature Reviews Neuroscience, 12(12), 723–738. https://doi.org/10.1038/nrn3114